Bulimia Nervosa News and Research

RSS

Bulimia nervosa is a type of eating disorder. It is often called just bulimia. A person with bulimia eats a lot of food in a short amount of time. This is called binging. The person may fear gaining weight after a binge. Binging also can cause feelings of shame and guilt. So, the person tries to "undo" the binge by getting rid of the food. This is called purging.

New initiative launched to create more effective ED therapies based on brain imaging studies

Current treatments for anorexia and bulimia nervosa, which afflict an estimated 10 to 24 million Americans, are often limited and ineffective.

12 Apr 2013

New report addresses presence of cerebral abnormalities in eating disorders

A report from the University of Freiburg that is published in one of the last issue of Psychotherapy and Psychosomatics address the presence of cerebral abnormalities in eating disorders.

3 Apr 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

APS to present scientific abstracts at Experimental Biology 2013

The American Physiological Society is one of six scientific societies sponsoring the meeting Experimental Biology 2013, being held April 20-24, 2013 at the Boston Convention and Exhibition Center, in Boston, Mass.

21 Mar 2013

New systems of classification of mental disorders may supplement diagnostic formulations

This paper introduce new systems of classification of mental disorders that may supplement diagnostic formulations. Characterizing each stage of an illness demarcates major prognostic and therapeutic differences among patients who otherwise seem to be deceptively similar since they share the same psychiatric diagnosis.

24 Jan 2013

Eating disorders common in adolescents attending emergency department

A significant percentage of adolescents attending hospital emergency response departments have eating disorders, suggest results from a US study.

22 Nov 2012

Eating disorders linked with poor decision-making skills

Spanish study results demonstrate that individuals with eating disorders may be worse decision-makers than those without such conditions.

20 Nov 2012

New bulimia nervosa therapy for patients with eating disorders

An eating disorders research team led by Stephen Wonderlich, a Director of Clinical Research at the Neuropsychiatric Research Institute (NRI), has developed a successful bulimia nervosa therapy that can provide patients an alternative for treating this debilitating disorder.

18 Nov 2012

Thin ideal internalization: an interview with Jessica Suisman and Kelly Klump

Thin-ideal internalization is the extent to which a person identifies with the cultural ideal that thinness is equivalent to attractiveness.

23 Oct 2012

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

Chicago psychological center serves as model for treatment of binge eating

As experts discuss major changes in binge eating, a Chicago psychological center serves as a model for treatment of the most common eating disorder.

5 Jun 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

Eating disorders can be triggered by lack of support following traumatic events

Eating disorders can be triggered by lack of support following traumatic events such as bereavement, relationship problems, abuse and sexual assault, according to research published in the May issue of the Journal of Clinical Nursing. Even changing school or moving home can prove too much for some young people and lead to conditions such as anorexia or bulimia.

25 Apr 2012

Israel says no to skinny models

The Israeli Parliament has moved to ban skinny models from appearing in that nation's media. It has won approval in Tel Aviv on Monday, and to American experts on eating disorders, the measure is a clear step toward a key goal: promoting more realistic body images among girls and women.

25 Mar 2012

Potential efficacy of specialized psychotherapy in bulimia nervosa and binge eating disorder

An investigation published in the current issue of Psychotherapy and Psychosomatics addresses the potential efficacy of a specialized psychotherapy in bulimia nervosa and binge eating disorder.

15 Mar 2012

Majority of women reach highest-ever weight after onset of bulimia

Researchers at Drexel University have found that a majority of women with bulimia nervosa reach their highest-ever body weight after developing their eating disorder, despite the fact that the development of the illness is characterized by significant weight loss.

1 Mar 2012

Lightlake intends to develop a treatment for premenstrual syndrome overeating

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.

7 Jan 2012

Deficits in endocannabinoid function may contribute to eating disorders

A new report in Biological Psychiatry suggests that deficits in endocannabinoid function may contribute to anorexia nervosa and bulimia.

1 Nov 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

ADA releases new position paper, 'Nutrition Intervention in the Treatment of Eating Disorders'

As one of the most complicated sets of illnesses to treat, eating disorders have mental health, as well as medical and nutritional, aspects. While treatment by a multidisciplinary health-care team is considered the best practice, there is considerable debate over how to most effectively treat eating disorders and who should be on a treatment team.

2 Aug 2011